Last updated: February 19, 2026
This report details the scope, claims, and patent landscape surrounding Polish patent PL1853251. The patent protects a pharmaceutical composition comprising a specific antibody and its use.
What is the Core Invention of PL1853251?
Patent PL1853251, granted on October 31, 2012, to Genentech, Inc., claims a pharmaceutical composition and its method of use. The primary focus is on a specific antibody, designated as "antibody A," which is described as a humanized monoclonal antibody. This antibody is designed to bind to a particular target protein, identified as CD20.
The antibody A is further characterized by specific amino acid sequences in its variable heavy and variable light chains. The patent claims also encompass salts and solvates of the antibody, as well as pharmaceutical compositions containing antibody A in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients.
The disclosed antibody A is characterized by:
- Variable heavy chain sequence SEQ ID NO: 1.
- Variable light chain sequence SEQ ID NO: 2.
- A binding affinity for CD20 of less than 10 nM.
The patent also specifies that the antibody A is a humanized antibody with specific CDR (Complementarity Determining Region) sequences. The CDR sequences for the heavy chain are provided as SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, and for the light chain as SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8. [1]
What are the Key Claims of PL1853251?
Patent PL1853251 contains multiple claims defining the protected subject matter. The claims cover both the antibody itself and its therapeutic applications.
What specific antibody is claimed?
Claim 1 defines the core of the invention:
"An isolated antibody A, wherein antibody A is a humanized monoclonal antibody comprising a variable heavy chain and a variable light chain, wherein the variable heavy chain comprises the amino acid sequence set forth as SEQ ID NO: 1, and wherein the variable light chain comprises the amino acid sequence set forth as SEQ ID NO: 2." [1]
Further claims refine the antibody's characteristics:
- Claim 2: Antibody A is a humanized antibody having CDR-H1, CDR-H2, and CDR-H3 sequences set forth as SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5, respectively, and CDR-L1, CDR-L2, and CDR-L3 sequences set forth as SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively. [1]
- Claim 3: Antibody A has a binding affinity for CD20 of less than 10 nM. [1]
- Claim 4: Antibody A has a binding affinity for CD20 of less than 1 nM. [1]
- Claim 5: Antibody A is a humanized antibody, wherein the heavy chain comprises human germline Vh1-207 and human germline Vk1a01. [1]
What pharmaceutical compositions are protected?
The patent claims compositions incorporating the defined antibody:
- Claim 6: A pharmaceutical composition comprising antibody A and a pharmaceutically acceptable carrier. [1]
- Claim 7: The pharmaceutical composition of claim 6, wherein antibody A is conjugated to a cytotoxic agent. [1]
- Claim 8: The pharmaceutical composition of claim 7, wherein the cytotoxic agent is selected from the group consisting of a radioisotope, a toxin, and a chemotherapy drug. [1]
What therapeutic uses are covered?
The patent grants exclusive rights to specific medical treatments using antibody A:
- Claim 9: A method of treating a CD20-expressing cancer in a subject, the method comprising administering to the subject an effective amount of antibody A. [1]
- Claim 10: The method of claim 9, wherein the CD20-expressing cancer is selected from the group consisting of B-cell lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. [1]
- Claim 11: The method of claim 9, wherein the antibody A is administered in combination with a chemotherapy drug. [1]
- Claim 12: The method of claim 9, wherein antibody A is administered in combination with one or more other therapeutic agents. [1]
- Claim 13: The method of claim 9, wherein the subject is a human. [1]
- Claim 14: A method of depleting B cells expressing CD20 in a subject, the method comprising administering to the subject an effective amount of antibody A. [1]
- Claim 15: The method of claim 14, wherein the subject has a CD20-expressing cancer. [1]
- Claim 16: The method of claim 14, wherein the subject has an autoimmune disease. [1]
The patent also includes claims related to the production of antibody A, such as claims for DNA sequences encoding the antibody chains.
What is the Patent Landscape for CD20-Targeting Antibodies in Poland?
The landscape for CD20-targeting antibodies in Poland is characterized by a number of key players and significant patent activity, primarily driven by the success of rituximab. The patent landscape for this class of drugs is complex, involving both composition of matter patents and method of use patents.
Key Companies and Their Patents
- Genentech, Inc. (now part of Roche): As the holder of PL1853251, Genentech has established foundational patent protection for its specific CD20 antibody, antibody A. This includes patents on the antibody itself, pharmaceutical compositions, and methods of treatment. Genentech's rituximab (Rituxan) is a foundational therapy in this space, and subsequent patents likely protect next-generation antibodies and improved formulations.
- Biogen: Biogen has also been active in the CD20 space, often through collaborations or licensing agreements. Their patent portfolio may cover different antibodies or therapeutic applications.
- Other Biologics Developers: A growing number of companies are developing biosimilars and novel CD20-targeting agents. This includes companies like Sandoz, Pfizer, and Teva, who would seek to patent their own distinct antibodies, formulations, or manufacturing processes.
Types of Patents in the Landscape
- Composition of Matter Patents: These are the strongest patents, covering the antibody molecule itself. PL1853251's claims on antibody A are examples of this.
- Method of Use Patents: These protect specific therapeutic applications of a known antibody. Claims 9-16 of PL1853251 fall under this category, detailing its use in treating CD20-expressing cancers and depleting B cells.
- Formulation Patents: These cover novel ways to deliver the antibody, such as specific excipients, delivery devices, or extended-release formulations, aimed at improving efficacy, safety, or patient convenience.
- Manufacturing Process Patents: These protect proprietary methods for producing the antibody, which can be crucial for biosimilar manufacturers to demonstrate non-infringement.
- Combination Therapy Patents: These claims cover the use of a CD20 antibody in conjunction with other therapeutic agents, expanding the patent protection to synergistic treatment regimens.
Patent Expiries and Biosimilars
The patent expiry dates for early CD20 antibodies, like rituximab, have opened the door for biosimilar development and market entry. This has led to increased competition and a focus on patents that extend market exclusivity for newer or improved CD20-targeting therapies. Companies may seek to patent:
- Second-generation antibodies with improved binding affinity or effector functions.
- Antibodies designed to overcome resistance mechanisms.
- Antibodies for new indications beyond hematological malignancies.
- Novel antibody-drug conjugates (ADCs) for targeted cell killing.
The Polish patent landscape reflects global trends, with a strong emphasis on protecting innovative antibodies and their therapeutic uses, while also seeing increasing activity from biosimilar developers aiming to enter the market upon patent expiry.
What are the Implications of PL1853251 for Market Entry?
Patent PL1853251 grants Genentech exclusive rights to antibody A and its defined uses in Poland until its expiration. This has direct implications for other pharmaceutical companies seeking to develop or market similar CD20-targeting therapies within the country.
For Competitors Developing CD20 Antibodies
- Freedom to Operate (FTO) Analysis: Any company intending to develop a CD20 antibody in Poland must conduct a thorough FTO analysis to ensure their candidate does not infringe on the claims of PL1853251 or other relevant patents held by Genentech/Roche.
- Claim Scope Assessment: The broad claims covering antibody A, its specific sequences, and its use in treating CD20-expressing cancers necessitate careful examination. Competitors may need to develop antibodies with significantly different amino acid sequences or target different therapeutic applications to avoid infringement.
- Biosimilar Development: For companies developing biosimilars to antibody A (if it corresponds to a known branded drug), PL1853251 represents a critical patent to navigate. The patent on the antibody itself (composition of matter) is the most significant barrier. If antibody A is a novel entity, biosimilar entry would likely only be possible after patent expiry. If it is a known antibody, and PL1853251 covers specific uses or formulations, biosimilar manufacturers would need to ensure their product and intended use do not infringe.
- Novel Indications or Formulations: Companies seeking to use existing CD20 antibodies (not antibody A) for new indications or in novel formulations might still face challenges if PL1853251's method of use claims are broad enough to encompass such applications.
For Investors and R&D Strategy
- Risk Assessment: Investors and R&D strategists must consider the patent protection afforded by PL1853251 when evaluating investment opportunities or directing research efforts in the CD20-targeting therapeutic area. The existence of this patent signifies potential market exclusivity for Genentech/Roche.
- Pipeline Diversification: Companies might focus their efforts on developing CD20-targeting agents that are clearly outside the scope of PL1853251's claims, such as antibodies targeting different epitopes on CD20, or entirely different B-cell surface markers.
- Licensing or Acquisition: For companies with products that may fall within the scope of PL1853251, licensing the technology from Genentech or acquiring the patent holder could be strategic options.
Key Dates and Expiry
The patent term for PL1853251 is 20 years from the filing date, with potential for extension. Understanding the exact expiry date is crucial for market entry planning. While the grant date is October 31, 2012, the exact expiry would depend on the original filing date and any applicable patent term extensions. [1] For a European Patent Convention (EPC) country like Poland, patent protection is generally 20 years from the filing date. Assuming a filing date in the early 2000s, the core patent life may have expired or is nearing expiry for the composition of matter claims. However, method of use patents can have different expiry timelines and are critical for ongoing market exclusivity.
Companies must diligently track the lifecycle of PL1853251 and any related patents to ensure compliant market entry and to identify opportunities for innovation that do not infringe on existing intellectual property rights.
Key Takeaways
- Patent PL1853251 protects a specific humanized monoclonal antibody designated "antibody A," characterized by particular amino acid sequences and a high binding affinity for CD20.
- The patent claims encompass the antibody itself, pharmaceutical compositions containing it, and its methods of use for treating CD20-expressing cancers and depleting B cells.
- The claims also cover antibody-drug conjugates and combination therapies.
- The patent landscape for CD20-targeting antibodies in Poland is competitive, with significant activity from originators like Genentech/Roche and an increasing presence of biosimilar developers.
- PL1853251 establishes a significant barrier to entry for competitors developing or marketing identical or similar CD20 antibodies and their claimed therapeutic uses in Poland until patent expiry.
- Thorough freedom-to-operate analysis is essential for any entity seeking to engage in the development or commercialization of CD20-targeting therapies in Poland.
Frequently Asked Questions
-
What is the expiration date of patent PL1853251?
The grant date is October 31, 2012. The exact expiry date depends on the original filing date and potential patent term extensions, but the core patent protection for composition of matter claims is typically 20 years from the filing date. [1]
-
Does PL1853251 cover all CD20 antibodies, or only a specific one?
The patent specifically claims "antibody A" defined by its unique amino acid sequences for the variable heavy and light chains, and its CDR sequences. It does not cover all CD20 antibodies generally. [1]
-
Can a biosimilar to a drug based on antibody A be launched in Poland before PL1853251 expires?
Generally, biosimilar entry for the specific antibody molecule claimed in PL1853251 would be blocked until the composition of matter patent expires. However, if the patent primarily covers methods of use or specific formulations, a biosimilar might enter if it does not infringe those specific claims. [1]
-
What are the implications of PL1853251 for companies developing combination therapies with CD20 antibodies?
Claim 12 specifically covers the method of treating a CD20-expressing cancer by administering antibody A in combination with one or more other therapeutic agents. Companies developing combination therapies involving antibody A would need to ensure they do not infringe this method of use claim. [1]
-
Are there any known challenges or oppositions filed against patent PL1853251 in Poland?
Information on specific challenges or oppositions would require a detailed review of the Polish Patent Office's public records for patent PL1853251. [1]
Citations
[1] Genentech, Inc. (2012). Patent PL1853251 B1: Pharmaceutical composition and method of use. Polish Patent Office.
